Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Kezar Life Sciences (KZR) Receivables - Other (2023 - 2025)

Kezar Life Sciences (KZR) has disclosed Receivables - Other for 3 consecutive years, with $184000.0 as the latest value for Q4 2025.

  • For Q4 2025, Receivables - Other changed N/A year-over-year to $184000.0; the TTM value through Dec 2025 reached $184000.0, changed N/A, while the annual FY2025 figure was $184000.0, N/A changed from the prior year.
  • Receivables - Other hit $184000.0 in Q4 2025 for Kezar Life Sciences, down from $1.7 million in the prior quarter.
  • Across five years, Receivables - Other topped out at $2.4 million in Q1 2024 and bottomed at $184000.0 in Q4 2025.
  • Average Receivables - Other over 3 years is $1.3 million, with a median of $1.5 million recorded in 2024.
  • On a YoY basis, Receivables - Other climbed as much as 248.2% in 2025 and fell as far as 27.67% in 2025.
  • Kezar Life Sciences' Receivables - Other stood at $695000.0 in 2023, then fell by 28.06% to $500000.0 in 2024, then tumbled by 63.2% to $184000.0 in 2025.
  • According to Business Quant data, Receivables - Other over the past three periods came in at $184000.0, $1.7 million, and $1.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.